Splenectomy in idiopathic hypersplenism.

Area of Science:

• Hematology
• Surgical Oncology
• Internal Medicine

Background:

• Idiopathic hypersplenism is a condition characterized by an enlarged spleen that destroys blood cells prematurely.
• Treatment options for idiopathic hypersplenism aim to reduce spleen size or function to improve blood cell counts.

Purpose of the Study:

• To evaluate the therapeutic efficacy and safety of splenectomy in patients diagnosed with idiopathic hypersplenism.
• To assess the impact of splenectomy on hematological parameters, including thrombocytopenia, anemia, and leukopenia.

Main Methods:

• A retrospective study involving 15 patients with idiopathic hypersplenism who underwent splenectomy.
• Analysis of pre- and post-operative hematological parameters, including platelet count, hemoglobin levels, and white blood cell count.
• Evaluation of treatment response (complete response, partial response, no response), morbidity, and mortality rates.

Main Results:

• Splenectomy demonstrated significant improvements in hematological parameters: 71% CR for thrombocytopenia, 83% CR for anemia, and 78% CR for leukopenia.
• The study reported a high morbidity rate of 27% and a concerning mortality rate of 20% post-splenectomy.
• Patient age and presence of multisystem disease were identified as critical factors influencing outcomes.

Conclusions:

• Splenectomy is a highly effective treatment for improving hematological parameters in idiopathic hypersplenism.
• The significant morbidity and mortality associated with splenectomy necessitate careful patient selection, particularly excluding elderly individuals and those with multisystem diseases.